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The type III-A CRISPR-Cas system is
capable of RNA-guided DNA and RNA
cleavage in vivo, revealing a highly
versatile mechanism of CRISPR immunity
that protects microorganisms against
diverse DNA and RNA invaders.
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Immune systems must recognize and destroy
different pathogens that threaten the host. CRISPR-
Cas immune systems protect prokaryotes from viral
and plasmid infection utilizing small CRISPR RNAs
that are complementary to the invader’s genome
and specify the targets of RNA-guided Cas nucle-
ases. Type III CRISPR-Cas immunity requires target
transcription, and whereas genetic studies demon-
strated DNA targeting, in vitro data have shown
crRNA-guided RNA cleavage. The molecular mecha-
nism behind these disparate activities is not known.
Here, we show that transcription across the tar-
gets of the Staphylococcus epidermidis type III-A
CRISPR-Cas system results in the cleavage of the
target DNA and its transcripts, mediated by indepen-
dent active sites within the Cas10-Csm ribonucleo-
protein effector complex. Immunity against plas-
mids and DNA viruses requires DNA, but not RNA,
cleavage activity. Our studies reveal a highly versa-
tile mechanism of CRISPR immunity that can defend
microorganisms against diverse DNA and RNA
invaders.
INTRODUCTION
CRISPR (clustered regularly interspaced short palindromic
repeats) loci and their associated (cas) genes encode a prokary-
otic adaptive immune system that provides protection against
foreign nucleic acids such as viruses (Barrangou et al., 2007)
and plasmids (Marraffini and Sontheimer, 2008). In this pathway,
resistance is specified by sequences derived from past invaders
that lie within the CRISPR loci interspersed between repeat ele-
ments, called spacers (Bolotin et al., 2005; Mojica et al., 2005;
Pourcel et al., 2005). Repeats and spacers are transcribed into
a long precursor crRNA (pre-crRNA). This precursor is pro-
cessed into small interfering CRISPR RNAs (crRNAs) that
together with Cas proteins assemble into a ribonucleoprotein
(RNP) complex that uses the crRNA as a guide to locate and
degrade the target nucleic acid (Brouns et al., 2008; van der
Oost et al., 2014). Based on cas gene content, CRISPR-Cas sys-
tems have been categorized into three major types (I–III) (Makar-1164 Cell 161, 1164–1174, May 21, 2015 ª2015 Elsevier Inc.ova et al., 2011b). In type III systems, pre-crRNA processing
is carried out by Cas6, a repeat-specific endoribonuclease
(Carte et al., 2008; Hatoum-Aslan et al., 2014). Cas6 cleavage
at repeat sequences generates crRNAs containing a full spacer
sequence flanked by an 8-nt repeat sequence at the 50 end
(the crRNA ‘‘tag’’) and the rest of the repeat at the 30 (Carte
et al., 2008; Marraffini and Sontheimer, 2008). A yet-uncharac-
terized nuclease is involved in further trimming of the 30 end
repeat sequence to produce a heterogeneous population of
mature crRNA species that differ by 6 nt in length (Hatoum-Aslan
et al., 2011, 2013).
Type III CRISPR-Cas systems are further classified into III-A
and III-B subtypes. Both systems harbor the type III-defining
cas10 gene, but they are distinguished by the content of acces-
sory genes: csm for III-A systems and cmr for type III-B (Makar-
ova et al., 2011b). The crRNA-guided targeting of nucleic acids
by type III-A CRISPR-Cas systems is highly sophisticated.
In vivo, targeting requires the lack of homology between the
crRNA tag and the target 50 flanking sequence (Marraffini and
Sontheimer, 2010). This requirement is thought to distinguish
between bona fide targets on invading nucleic acids from the
CRISPR array itself, where the presence of repeat sequences
will lead to full homology with the crRNA tag and prevent autoim-
munity. In addition, transcription across the target is required
for targeting in vivo (Goldberg et al., 2014). The nature of the
target nucleic acid has been controversial. In vivo genetic
assays demonstrated DNA targeting for the type III-A system
of Staphylococcus epidermidis (Goldberg et al., 2014; Hatoum-
Aslan et al., 2014; Marraffini and Sontheimer, 2008) but RNA
targeting for the Streptococcus thermophilus system (Tamulaitis
et al., 2014). Recently, crRNA-guided RNA targeting has been
shown in vitro (Staals et al., 2014; Tamulaitis et al., 2014);
however, direct demonstration of DNA cleavage has not been
provided yet.
Here, we performed in vivo and in vitro experiments with the
type III-A CRISPR-Cas system of S. epidermidis, which demon-
strate dual crRNA-guided cleavage of the target DNA and its
transcripts. We show that purified Cas10-Csm complexes
cleave double-stranded DNA targets. The reaction absolutely re-
quires transcription across the target, and it is inhibited by the
presence of homology between the crRNA tag and the 50 target
flanking sequence. The same complex is also capable of crRNA-
guided RNA cleavage in vitro, and this reaction is not prevented
by crRNA tag homology. In vivo, type III-A targeting of a plasmid
shows degradation of the DNA upon induction of transcription
Figure 1. crRNA-Guided Co-transcriptional DNA Cleavage by the
S. epidermidis Cas10-Csm Complex
(A)S. epidermidisRP62a carries aCRISPR-Cas locus that harbors four repeats
(black boxes), three spacers (colored boxes), and nine cas/csm genes, five of
which (highlighted in blue) encode for the Cas10-Csm ribonucleoprotein
complex.
(B) The first spacer sequence (spc1) generates a mature crRNA that targets a
complementary sequence in the nickase gene (nes) present in most staphy-
lococcal conjugative plasmids (green). The most abundant mature crRNA
species contains 33 nt of spacer sequence as well as 8 nt of repeat sequences
at its 50 end, known as the crRNA tag (light green).
(C) SDS-PAGE of the Cas10-Csm complex purified from E. coli.
(D) Schematic of the co-transcriptional DNA cleavage assay of a dsDNA
substrate containing the nes target. Arrowheads indicate the approximate
cleavage site detected in (E).
(E and F) Denaturing PAGE and autoradiography of the products of two co-
transcriptional dsDNA cleavage assays differing in the location of the radio-
active label: (E) non-template strand; (F) template strand. Cleavage products
were collected at 30, 60, 90, and 120 min. Reactions in which each of the
components of the assay were omitted in a 120-min assay are shown as
controls.across the target, as well as a precise cut of the target transcript.
We also show that DNA and RNA targeting are independent
events. Whereas DNA targeting requires an intact Cas10 palmpolymerase domain, RNA targeting requires a nucleolytic active
site in Csm3, both in vitro and in vivo. Mutations that affect DNA
cleavage do not affect RNA cleavage and vice versa. Finally,
in vivo experiments show that DNA, but not RNA, cleavage is
required for immunity against plasmids and DNA viruses. These
results consolidate all the different mechanistic observations of
type III-A targeting into a single model and uncover a highly elab-
orate targeting strategy distinct from the type I and type II
CRISPR-Cas systems studied so far (Barrangou and Marraffini,
2014).
RESULTS
crRNA-Guided DNA Cleavage by the Cas10-Csm
Complex Requires Target Transcription
Whereas genetic evidence demonstrated DNA targeting for the
S. epidermidis type III-A CRISPR-Cas system (Goldberg et al.,
2014; Hatoum-Aslan et al., 2014; Marraffini and Sontheimer,
2008), direct evidence of DNA cleavage has been elusive. We
previously showed that the S. epidermidis CRISPR-Cas locus
(Figure 1A) encodes for a ribonucleoprotein complex composed
of Cas10, Csm2, Csm3, Csm4, Csm5, and the crRNA guide,
known as the Cas10-Csm complex (Hatoum-Aslan et al., 2013,
2014). One of the crRNAs (encoded by the first spacer, spc1)
matches a region of the nickase gene present in most staphylo-
coccal conjugative plasmids (Marraffini and Sontheimer, 2008);
this region was selected as the target for our in vivo and
in vitro studies (Figure 1B). We expressed these proteins in
Escherichia coli to purify the complex to homogeneity (Fig-
ure 1C). The complex was co-expressed with the repeat-spacer
array, and therefore it is loaded with the mature crRNA species
that differ by increments of 6 nt (Figure S1A). As observed for
other type III-A CRISPR-Cas systems (Staals et al., 2014; Tamu-
laitis et al., 2014), the Cas10-Csm complex was incapable of
cleaving a complementary single-stranded DNA (ssDNA) or
double-stranded DNA (dsDNA) oligonucleotide substrates in
different assay conditions (Figures S1B and S1C). Recently, we
reported that transcription of the target sequence is required
for type III-A CRISPR immunity (Goldberg et al., 2014). In order
to test whether target transcription facilitates DNA cleavage,
we used an oligonucleotide-based RNAP transcription system,
where stepwise assembly of purified RNA and DNA oligonucleo-
tides and E. coli core RNA polymerase can reconstitute fully
functional RNAP elongation complexes (Sidorenkov et al.,
1998). In this assay, each oligonucleotide (the RNA primer, the
template strand or the non-template strand) can be radioactively
labeled prior to assembly to follow their fate in the reaction. The
DNA oligonucleotides were complementary to each other and
contained the nes target (35 nt complementary to the spc1
crRNA) and its flanking sequences (24 nt on each side). The elon-
gation complex is assembled in the presence of transcription
buffer containing Mg2+ by the annealing of an RNA primer to
the template strand, followed by the addition of RNAP and the
annealing of the non-template strand (Figure 1D). Assembled
elongation complexes were incubated with purified Cas10-
Csm, and transcription was started by supplementing rNTPs.
Extension of 50-radiolabeled RNA primers confirmed transcrip-
tion elongation (Figure S1D). We labeled each strand of theCell 161, 1164–1174, May 21, 2015 ª2015 Elsevier Inc. 1165
Figure 2. RNAP Elongation Is Required for
Cas10-Csm Target Cleavage
(A) The small molecule CBR703 inhibits RNAP
elongation and was tested in our DNA cleavage
assay to corroborate the transcription requirement
for cleavage.
(B) CBR703 inhibits transcription elongation.
Using a radiolabeled RNA primer, we measured
transcription elongation in different conditions in
the presence (1 mM) or absence of CBR703.
Extension products were collected at 30, 60, 90,
and 120 min. Reactions in which each of the
components of the assay was omitted in a 120-
min assay are shown as controls.
(C) In vitro DNA cleavage assay using a radio-
labeled non-template strand (as in Figure 1E) in
the presence (1 mM) or absence of CBR703. Re-
action products were collected at 30, 60, 90, and
120 min. Reactions in which each of the compo-
nents of the assay was omitted in a 120-min assay
are shown as controls.substrate in different experiments and analyzed the products of
the reaction by denaturing PAGE and autoradiography. We de-
tected cleavage of the non-template strand at two defined sites,
only after the start of transcription by the addition of rNTPs
(compare lanes 3 and 4–7, Figure 1E). Interestingly, an estima-
tion of the cleavage sites based on the size of the product indi-
cates that it occurred on the 30 flanking side of the target, not
within the region with complementary to the crRNA (Figure 1D).
Further DNA degradation to the nucleotide level was observed
with longer incubation times (Figure 1E). The template strand,
in contrast, was neither cleaved nor degraded (Figure 1F). To un-
equivocally demonstrate a transcription requirement for DNA
cleavage, we used an RNAP elongation inhibitor, CBR703 (Artsi-
movitch et al., 2003). This small molecule inhibitor prevents
nucleotide addition during transcription and therefore it should
impair DNA cleavage by the Cas10-Csm complex (Figure 2A).
First we corroborated that the addition of CBR703 prevents effi-
cient transcription elongation in our assay, by radiolabeling the
RNA primer (Figure 2B). When the same assay was performed
using a radiolabeled non-template strand, the inhibition of tran-
scription elongation with CBR703 prevented DNA cleavage
(Figure 2C). Altogether these results reveal the molecular mech-
anism of type III-A DNA targeting: transcription-dependent DNA
cleavage of the non-template strand.
Two previous genetic observations revealed an unexpected
targeting mechanism for type III-A systems. First, only crRNAs
complementary to the non-template strand provide efficient
immunity (Goldberg et al., 2014) (Figures S2A and S2B). Second,
the prevention of autoimmunity in type III-A systems, i.e., the
spc1 crRNA-guided targeting of spc1 DNA in the CRISPR array,
requires homology between the crRNA tag and the repeat se-1166 Cell 161, 1164–1174, May 21, 2015 ª2015 Elsevier Inc.quences that flank the 30 end of the
spacer DNA (of the targeted strand,
complementary to the crRNA spacer
sequence) (Marraffini and Sontheimer,
2010) (Figure S2C). Presumably this isachieved by the pairing between these sequences. The develop-
ment of an in vitro DNA cleavage assay allowed us to test
whether the lack of immunity observed in these two genetic ex-
periments reflects an abrogation of target DNA cleavage by the
Cas10-Csm complex. To test for DNA cleavage mediated by a
crRNA complementary to the template strand, we used an
RNA primer that anneals to the top strand of our dsDNA sub-
strate to assemble the elongation complex (Figure 3A). Incuba-
tionwith the Cas10-Csmcomplex in identical conditions to those
that led to cleavage of the non-template strand produced no
cleavage of either strand (Figure 3B), even in the presence of
target transcription (Figure S1D). To test for DNA cleavage in
the anti-autoimmunity scenario, we modified the target to intro-
duce the corresponding repeat sequences at the 30 flank of the
spc1 crRNA complementarity region (Figure 3C). We then
assembled the elongation complex and tested for cleavage of
each DNA strand. We did not detect any cleavage or degrada-
tion, regardless of target transcription (Figure 3D). This result
indicates that, in addition to target transcription, DNA cleavage
requires mismatches between the crRNA tag and the 30 flanking
region of the target, thus providing the molecular basis for the
prevention of autoimmunity, a central feature of all immune
systems.
crRNA-Guided RNA Cleavage by the Cas10-Csm
Complex
Recently, it has been reported that type IIIA in Streptococcus
thermophilus and Thermus thermophilus can cleave ssRNA tar-
gets (Staals et al., 2014; Tamulaitis et al., 2014), a function that
allows protection against RNA viruses (Tamulaitis et al., 2014).
In both of these systems, the Cas10-Csm complex cleaves
Figure 3. In Vitro Cleavage Reflects In Vivo
Targeting
(A) Schematic of the substrate used to test for DNA
cleavage in conditions where the crRNA matches
the template strand.
(B) In vitro DNA cleavage assay of the substrate
shown in (A), with the radiolabel either in the
template (left autoradiography) or non-template
(right) strand. Reaction products were collected at
30, 60, 90, and 120 min. Reactions in which each
of the components of the assay was omitted in a
120-min assay are shown as controls.
(C) Schematic of the ‘‘anti-tag’’ substrate in which
the flanking sequence downstream on the nes
target matches the 50 crRNA tag (light green),
generating a full match between the crRNA and
the DNA target.
(D) In vitro DNA cleavage assay of the substrate
shown in (C), with the non-template strand radio-
labeled. Reaction products were collected at 30,
60, 90, 120, and 180 min. Reactions in which each
of the components of the assay was omitted in a
120-min assay are shown as controls.RNA at multiple sites at 6-nt intervals. We also investigated the
ribonuclease activity of the S. epidermidis complex. A 55-nt,
50-radiolabeled ssRNA substrate complementary to spc1 crRNA
(Figure 4A) was incubated with the Cas10-Csm complex in a
buffer containing Mg2+, and the reaction was subjected to
denaturing gel separation and autoradiography. We observed
sequence specific endoribonuclease activity against the ssRNA
substrate complementary to spc1 crRNA, with multiple cleavage
products showing the reported 6-nt periodicity (Figure 4C; Fig-
ures S3A and S3B). No activity was observedwith a 55-nt scram-
bled, control RNA substrate (Figures S3C and S3D). A conserved
aspartate residue in Csm3 (D32 in the S. epidermidis homolog)
was identified to be the active site residue responsible for
the endoribonuclease activity in the S. thermophilus and
T. thermophilus complexes (Staals et al., 2014; Tamulaitis
et al., 2014). We made the corresponding alanine substitution,
D32A, purified the Cas10-Csm(Csm3D32A) complex, and tested
its activity against ssRNA substrates. The Csm3 D32A
mutant impaired RNA cleavage without affecting complex as-
sembly or crRNA maturation (Figures 4D and S1A), consistent
with a requirement for this conserved aspartate in the catalysis
of RNA cleavage. Finally, to interrogate the importance of
base-pairing between the crRNA tag and the 30-flanking
sequence of the target, we used an ssRNA substrate (anti-
tag nes ssRNA substrate, Figure 4B) with a sequence comple-
mentary to the tag. PAGE analysis of the reaction products
revealed that base-pairing between the 8-nt crRNA tag andCell 161, 1164–11the 30-flanking sequence of the target
had no effect on the ssRNA cleavage
pattern (Figure 4E). Collectively, the data
in Figures 4 and S3 corroborate
previous reports of crRNA-guided RNA
cleavage by type III-A CRISPR-Cas sys-
tems. More important, together with our
demonstration of DNA cleavage thesefindings reveal that type III-A immunity is capable of both RNA
and DNA targeting.
crRNA-Guided RNA and DNA Cleavage Are Independent
Activities within the Cas10-Csm Complex
Combined with the crRNA-guided RNA cleavage, the transcrip-
tion requirement for type III-A CRISPR-Cas immunity and
crRNA-guided DNA cleavage opens the possibility of a mecha-
nistic link between these two activities. For example, the RNA
cleavage of the target’s transcript could be required for DNA
cleavage. However, because experiments with substrates con-
taining a 30 flanking sequence capable of pairing with the crRNA
tag had opposite outcomes, i.e., DNA but not RNA cleavage was
affected (see above), our results suggest that these are indepen-
dent cleavage activities. To test this, we evaluated the DNA
cleavage activity of the Cas10-Csm(Csm3D32A) complex, inca-
pable of RNA cleavage. The mutant generated a similar DNA
cleavage pattern of the non-template strand to the wild-type
complex (Figure 5A, compare to Figure 1E). This demonstrates
that the Csm3 active site is not responsible for DNA cleavage
and that DNA targeting occurs independently of RNA cleavage.
Cas10 is the largest subunit of the type III-A effector complex
and contains a degenerate GGDEF motif (GGDD), resembling
the palm polymerase domain of DNA/RNA polymerases and nu-
cleotidyl cyclases (Anantharaman et al., 2010; Makarova et al.,
2011a). Previously, we reported that mutations in the palm
domain of cas10 (cas10G584A,G585A,D586A,D587A, here abbreviated74, May 21, 2015 ª2015 Elsevier Inc. 1167
Figure 4. crRNA-Guided RNA Cleavage by
the S. epidermidis Cas10-Csm Complex
(A) Base-pair interaction between the nes crRNA
and the 55-nt ssRNA target. Arrowheads showed
the cleavage sites detected in (C).
(B) ‘‘Anti-tag’’ ssRNA substrate used to evaluate
the effect of a full match between the crRNA guide
and the ssRNA substrate. Arrowheads showed the
cleavage sites detected in (E).
(C) In vitro ssRNA cleavage assay of the radio-
labeled substrate shown in (A). Reaction products
were collected at 0, 1, 2, 3, 4, 5, 7.5, 10, 15, 20,
and 30 min, separated by denaturing PAGE and
visualized by gel autoradiography.
(D) Same assay as in (C), using the mutant Cas10-
Csm(Csm3D32A) complex. Incubation times are 0,
5, 10, 20, 30, 60, 120, 180, and 240 min.
(E) Cleavage of the ‘‘anti-tag’’ ssRNA substrate
shown in (B); incubation times: 0, 5, 10, 15, 30, and
60 min.cas10palm) are required for type III-A immunity against staphylo-
coccal plasmids (Hatoum-Aslan et al., 2014). The mutant did not
show defects in either crRNAmaturation or Cas10-Csm complex
formation, suggesting that the palm polymerase domain could
play a catalytic role in plasmid targeting (Hatoum-Aslan et al.,
2014). To investigate this, we purified a Cas10-Csm complex
with alanine substitutions of the conserved aspartate residues
(Cas10D586A,D587A-Csm) and tested it for RNA or DNA nuclease
activity. Whereas the mutant complex cleaved the ssRNA sub-
strate with a similar pattern as the wild-type complex (Figure 5B,
compare to Figure 4C), it was defective in co-transcriptional DNA
cleavage (Figure 5C). These results demonstrate that the palm
polymerase domain of Cas10 plays an essential role in DNA
cleavage, with its two conserved aspartate residues most likely
involved in catalysis. Taken together, these data indicate that
crRNA-guided DNA cleavage activity of type III-A CRISPR-Cas
systems is independent from the crRNA-guided RNA cleavage,
catalyzed by two different active sites within the Cas10-Csm
complex.
Dual crRNA-Guided Cleavage of a DNA Target and Its
Transcripts during Type III-A CRISPR Immunity
Although the DNA and RNA cleavage activities of the Cas10-
Csm complex are independent, our data clearly indicate that
type III-A CRISPR-Cas systems can cleave both DNA and RNA
molecules. Moreover, the crRNAs that confer immunity and1168 Cell 161, 1164–1174, May 21, 2015 ª2015 Elsevier Inc.mediate DNA cleavage (which match the
non-template, not the template, DNA
strand) are also complementary to, and
can guide cleavage of, the target tran-
script (Figure 6A). It is therefore possible
that type III-A CRISPR immunity results
in the cleavage of both the target DNA
and its transcripts. To test this, we utilized
an inducible immunity assay in vivo. In this
assay, cells harbor a plasmid with the nes
target under the control of a tetracycline-inducible promoter, the pTarget plasmid. To study the effect of a
match between the 30 flanking target sequence and the crRNA
tag, we generated a mutant version of pTarget with mutations
upstream of the nes target that introduce this match
(the pTargetanti-tag plasmid, Figure S2C). Finally, the third strain
tested contained pE194, an empty vector control. These cells
are then transformed with a second plasmid encoding the type
III-A CRISPR-Cas system (wild-type or the mutant variants
Dspc1, cas10palm, or csm3D32A), the pCRISPR plasmid. Previous
studies confirmed the heterologous expression of the Cas10-
Csm complex from this plasmid (Hatoum-Aslan et al., 2013). In
the absence of the inducer, anhydrotetracycline (aTc), there is
no target transcription, and therefore there should be no immu-
nity against pTarget and its derivatives. Isolated transformants
can be treated with aTc to induce CRISPR immunity and follow
the fate of the target DNA and its transcripts (Figure 6B). First
we performed transformations and seeded plates with or without
aTc to measure CRISPR immunity. In the presence of aTc
(Figure 6C), cells harboring pTarget and the control pE194
plasmids had similarly high efficiency of transformation for
pCRISPR(Dspc1), which does not express the spc1 crRNA
guide, and for the DNA cleavage-deficient pCRISPR(cas10palm).
The efficiency of transformation of cells containing the
pTargetanti-tag with the wild-type pCRISPRwas also high. In con-
trast, transformation of the wild-type and csm3D32A pCRISPR
plasmids was greatly diminished in recipients harboring pTarget
Figure 5. The DNA and RNA Cleavage
Activities of the Cas10-Csm Complex Are
Independent
(A) Same DNA cleavage assay shown in Figure 1E
using the Cas10-Csm(Csm3D32A) complex.
(B) Same ssRNA cleavage assay shown in Fig-
ure 3C using the Cas10D586A,D587A-Csm complex;
incubation times: 0, 5, 10, 15, 30, and 60 min.
(C) Same DNA cleavage assay shown in Figure 1E
using the Cas10D586A,D587A-Csm complex. An
extra time point was taken at 180 min.but not pE194 or pTargetanti-tag. Collectively, these results
demonstrate that cleavage of the DNA target, but not its tran-
script, is required for CRISPR immunity against plasmids. As ex-
pected,whenweplated in the absence of the inducer (Figure 6D),
we measured a high efficiency of transformation for all plasmids.
An exception was the transformation of the pCRISPR(csm3D32A)
plasmid into cells harboring pTarget. In this case, we obtained a
decrease in the number of transformants of approximately three
orders of magnitude, with all of the colonies tested resulting in
‘‘escaper’’ mutants that either lacked the target or harbored re-
arranged pCRISPR(csm3D32A) plasmids (not shown). We do
not understand this gain-of-function phenotype, but we specu-
late that there is an increase of DNA targeting in the absence
of RNA targeting, which is highly susceptible to leaky expression
of the nes target in the absence of aTc. This could be due to the
presence of more Cas10-Csm complexes available for DNA
targeting in the absence of RNA targeting in this mutant. The
reduction in transformation efficiency was not observed when
pCRISPR(csm3D32A) was transformed into pE194-containing
cells or when a second, wild-type copy of csm3 was added
into the assay (data not shown).
Staphylococci containingboth the target andCRISPRplasmids
(pCRISPR/pTarget, pCRISPR/pTargetanti-tag, pCRISPR(Dspc1)/
pTarget and pCRISPR(cas10palm)/pTarget) obtained after trans-
formation in the absence of aTc were further analyzed to detect
DNA and/or RNA cleavage upon induction of target transcription.
Transformants were grown in liquid to an OD600 0.5 before the
addition of aTc. Plasmid DNA and total RNA were extracted
fromcells collected at different times after transcription induction.Cell 161, 1164–11The integrity of the plasmid DNA was
observed by agarose gel electrophoresis
followed by ethidium bromide staining
beforeandafter additionofaTc (Figure6E).
The different versions of pCRISPR are not
targeted and therefore serve as a loading
control for each lane. While the pTarget
was completely degraded in the presence
of a wild-type pCRISPR, it was detected
in cells containing the cas10palm mutation,
albeit at lower levels than in cells lacking
the spc1 crRNA. pTargetanti-tag was also
intact in the presence of the wild-type
pCRISPR. Analysis of pTarget degrada-
tion over time revealed the disappearance
of the supercoiled plasmid (Figure 6F).RNA cleavage was followed by primer extension of total RNA
with an oligonucleotide priming downstream of the nes target
transcript (Figure 6G). Extension of the full nes transcript (171 nt)
was detected in cells lacking the spc1 crRNA guide, but cleavage
products were observed for wild-type and cas10palm CRISPR-
Cas systems, with cleavage site within the nes target (Figure 6H).
Although in vitro we detected multiple cleavage sites, only the
nearest downstream cleavage site is detected in vivo, most likely
due to the impossibility of extending beyond the cut RNA. Cleav-
age of the anti-tag nes transcript was detected, although at a
position that maps downstream of the target (see Discussion).
Altogether, these results demonstrate that cleavage of the
target DNA, but not its transcripts, is required for type III-A
CRISPR-Cas immunity against plasmids. More importantly, the
data show that these systems are capable of co-transcriptional
DNA targeting resulting in the cleavage of both the target DNA
and its transcripts.
As opposed to our plasmid experiments, in which the target
transcript is not essential for plasmid replication, most viral tran-
scripts are essential for viral propagation. Therefore, we investi-
gated whether the dual DNA and RNA cleavage of the viral target
DNA and its transcripts is important for anti-phage immunity. We
tested the protection of staphylococci harboring different muta-
tions in the type III-A CRISPR-Cas locus against infection by the
dsDNA bacteriophage FNM1g6 (Goldberg et al., 2014). We tar-
geted the head protein gene gp43 (Figure 7A) and measured cell
survival (Figure 7B). As shown before (Goldberg et al., 2014), the
wild-type CRISPR-Cas system provided strong immunity. In
contrast, cells containing the cas10palm gene succumbed to74, May 21, 2015 ª2015 Elsevier Inc. 1169
Figure 6. crRNA-Guided Co-transcriptional
Cleavage of Plasmid DNA and Its Tran-
scripts during Type III-A CRISPR-Cas
Immunity
(A) Schematic of the dual crRNA-guided DNA and
transcript RNA cleavage (red cross). Target se-
quences are shown in green; the nuclease
responsible for the cleavage of each nucleic acid is
also indicated.
(B) Inducible anti-plasmid CRISPR immunity
assay. Staphylococci are transformed with two
plasmids: pCRISPR carrying the type III-A
CRISPR-Cas system of S. epidermidis and
pTarget harboring the nes target under the control
of the tetracycline-inducible promoter Ptet. In the
absence of the anhydro-tetracycine inducer (aTc),
the tetracycline repressor (TetR) prevents nes
transcription and therefore CRISPR immunity
against pTarget. Addition of aTc triggers immunity,
allowing following the fate of pTarget and its tran-
scripts over time.
(C) Transformation efficiencies of different
pCRISPR plasmids (wild-type or the mutant vari-
ants Dspc1, cas10palm or csm3D32A) into staphy-
lococci harboring different target plasmids (pE194,
pTarget, and pTargetanti-tag). Efficiency is calcu-
lated as the ratio of colony-forming units (cfu) per
microgram of plasmid DNA transformed (mean ±
SD of three replicas). Colonies were enumerated in
plates containing chloramphenicol and erythro-
mycin for the selection of pCRISPR and pTarget,
respectively, and aTc.
(D) Same as (C), but without supplementing plates
with aTc.
(E) pTarget transformants obtained in (D) were
cultured in liquid media supplemented with chlor-
amphenicol but without erythromycin. Cells were
collected at the beginning of the exponential
growth, before aTc was added (), and after 10 hr
of growth in the presence of the inducer (+).
Plasmid DNA was extracted, digested with XhoI,
separated by agarose gel electrophoresis and
stained with ethidium bromide. The fraction of
pTarget remaining after targeting relative to the
pCRISPR control is shown at the bottom of the gel
(mean ± SD of three replicas).
(F) Analysis of pTarget plasmid DNA at different times during type III-A CRISPR-Cas immunity (wild-type pCRISPR) or a non-targeting control (Dspc1 pCRISPR),
without XhoI digestion.
(G) Schematic of a primer extension assay designed to detect nes transcript cleavage during type III-A CRISPR-Cas immunity. A 50-radiolabeled (red dot) primer
(brown line) is used to initiate reverse transcription of the nes transcript, generating a 171-nt extension product in the absence of RNA cleavage, measured from
the priming site to the +1 transcription start determined by the Ptet promoter (arrow). The cleavage sites inferred from the results shown in (H) are indicated,
approximately 70 and 60 nt from the priming site (black and gray arrowheads, respectively).
(H) Primer extension analysis of the nes transcripts after addition of aTc in different targeting conditions. Times assayed: 0, 10, and 60min. Arrowheads indicated
the extension of the cleavage products.phage infection. The CRISPR-Cas systems containing the
csm3D32A mutation, which cannot cleave the target’s transcript,
provided similar immunity to the wild-type system, almost indis-
tinguishable from the protection conferred by the type II-A
CRISPR-Cas system of Streptococcus pyogenes (incapable of
RNA cleavage) targeting the same viral region (Figure 7). These
results support the hypothesis that DNA and RNA cleavage
activities are independent and that the crRNA-guided RNA
cleavage of the Cas10-Csm complex is not required for defense
against dsDNA viruses, at least in the conditions tested.1170 Cell 161, 1164–1174, May 21, 2015 ª2015 Elsevier Inc.DISCUSSION
Recently, we showed that the immunity provided by type III-A
CRISPR-Cas systems demands target transcription and that
only crRNAs complementary to the non-template (coding) strand
provide effective immunity (Goldberg et al., 2014). Previously, it
was shown that self versus non-self discrimination in these sys-
tems relies upon the differential base-pairing of the crRNA tag to
the target flanking sequences (Marraffini and Sontheimer, 2010),
rather than on the presence of the protospacer-adjacent motif
Figure 7. Immunity against dsDNA Viruses Requires the DNA, but
Not the RNA, Cleavage Activity of the Cas10-Csm Complex
(A) Sequence of the gp43 gene of the fNM1g6 staphylococcal dsDNA phage
(22,390–22,449 bp) targeted by both type III-A (green box) and type II-A (red
box) CRISPR-Cas systems.
(B) Staphylococci harboring different CRISPR-Cas systems targeting the gp43
gene as shown in (A) were grown in liquid media and infected with fNM1g6
phage (at 0 hr). Optical density wasmeasured for the following 10 hr tomonitor
cell survival due to CRISPR immunity against the phage.(PAM) of type I and II CRISPR-Cas targets (Bolotin et al., 2005;
Deveau et al., 2008; Mojica et al., 2009; Semenova et al.,
2011). Here, we reconstituted DNA cleavage by the type III-A
Cas10-Csm ribonucleoprotein complex in vitro, demonstrating
that (1) cleavage requires the transcription of the target DNA,
(2) only crRNA guides complementary to the non-template
strand can direct cleavage, (3) pairing between the crRNA tag
and the 30 flanking sequence of the target prevents cleavage,
and (4) the Cas10 palm polymerase domain is involved. Thus,
our biochemical results provide the molecular mechanism for
the most basic aspects of type III-A CRISPR-Cas immunity
against DNA mobile genetic elements. Intriguingly, the DNA
cleavage site lies outside the target sequence complementary
to the crRNA, mapping to the 30 flanking side of the target.
Perhaps the Cas10-Csm complex probes the base-pairing na-
ture between the 8-nt crRNA-tag and the 30-flanking sequence
of the target, to distinguish the CRISPR array from bona fide tar-
gets and avoid cleavage of the former. Our previous genetic data
suggested that DNA targeting requires transcription in cis (Gold-
berg et al., 2014). We speculate that co-transcriptional DNA
cleavage may result from either the separation of both DNA
strands or negative DNA supercoiling, both facilitated by translo-
cation of the transcriptional machinery along DNA. Accumulation
of negative supercoiling has been determined a requisite for
DNA cleavage by the type I-E CRISPR-Cas system (Westra
et al., 2012). Purification followed by mass spectrometry of the
Cas10-Csm complex from staphylococci showed the absence
of co-purifying RNAP subunits (Hatoum-Aslan et al., 2013,
2014), suggesting the absence of a detectable interaction
between both complexes. Our cleavage experiments indicate
that only the non-template strand is cleaved, raising the question
of how a single-strand break in the phage DNA can result in
strong immunity. Experiments using a nickase version of the
dsDNA nuclease EcoRI have shown that the introduction of
chromosomal DNA nicks is toxic to the cell, and even lethal inthe absence of the homologous recombination repair pathway
(Heitman et al., 1999). Presumably, the passage of a replication
fork through the ssDNA break creates more severe DNA lesions
that cannot be repaired by simple ligation and that induce the
SOS repair system. We believe that a similar scenario can apply
to the Cas10-Csm nickase activity on phage DNA targets: it
could lead to severe DNA damage that is not repaired efficiently,
preventing viral replication. This also could be the case for type
I-E systems, where the Cas3-Cascade complex has been re-
ported to introduce single-strand breaks on its DNA targets
(Westra et al., 2012). In vivo, following the target plasmid after
induction of CRISPR targeting, we cannot detect nicked nor
linearized DNA. Instead, we observe the disappearance of the
supercoiled form of the plasmid. We hypothesize that in vivo
the nicked plasmid species is rapidly degraded after cleavage.
In E. coli, and most certainly in staphylococci as well, the proc-
essivity of the major exonucleases RecBCD and RecJ can be
as high as 1 kb per second (Lovett and Kolodner, 1989; Roman
et al., 1992). At this rate of degradation, the nicked and/or linear
forms of a small plasmid such as pTarget (4.6 kb) will be
completely degraded in a few seconds and will not be detected
by ethidium bromide staining of plasmids subjected to agarose
gel electrophoresis. Alternatively, the Cas10-Csm complex itself
could degrade the target DNA. Supporting this hypothesis, our
results show that at longer incubation times the substrate’s
signal disappears (Figure 1E). Indeed, purified S. epidermidis
Cas10 has been shown to harbor ssDNA exonucleolytic activity,
although not in the context of the Cas10-Csm complex (Ramia
et al., 2014). It is possible that this exonuclease activity is faster
in vivo than in vitro and could be potentially responsible for the
rapid degradation of the target plasmid in vivo.
Two recent studies showed the crRNA-guided RNA cleavage
of the type III-A CRISPR-Cas systems of S. thermophilus and
T. thermophilus (Staals et al., 2014; Tamulaitis et al., 2014).
Here, we corroborated these results, and in addition we showed
that this RNase activity (1) is responsible for the cleavage of
target transcripts during in vivo type III-A CRISPR immunity
and (2) is not required for DNA cleavage. In vitro, cleavage is per-
formed by Csm3 within the Cas10-Csm complex and occurs at
6-nt intervals, each cut most likely executed by each of the mul-
tiple Csm3 subunits present in the complex. In vivo, primer
extension detects only one cleavage, within the crRNA:transcript
pairing region. We speculate that this is either due to the impos-
sibility to extend beyond the cut site or to a lower sensitivity of the
primer extension assay, which may be allowing us to visualize
only themost abundant cleavage products. Alternatively, cellular
RNases could degrade the longer cleavage products in vivo, but
not in vitro. Also, we detected different cleavage sites in the anti-
tag RNA target in vitro and in vivo. In vitro, the cleavage pattern is
similar to that the nes RNA target, whereas in vivo the extension
product is approximately 10 nt shorter, corresponding to a re-
gion downstream of the target transcript, within the tag:anti-
tag pairing region. It is possible that, in vivo, the RNA cleavage
site is measured from the first nucleotides that form the crRNA:
transcript pair (i.e., within the anti-tag region). If so, the cleavage
site of the anti-tag target will be further downstream to the wild-
type target, although we do not understand why this is not the
case in vitro. More importantly, the crRNA-guided RNA cleavageCell 161, 1164–1174, May 21, 2015 ª2015 Elsevier Inc. 1171
activity of the Cas10-Csm complex is not required for DNA
cleavage in vitro and in vivo. The S. thermophilus type III-A
CRISPR-Cas system was transplanted into E. coli and shown
that it can confer crRNA-guided immunity against the MS2
ssRNA phage that attacks this host (Tamulaitis et al., 2014).
Together with our results, the picture that emerges is that DNA
cleavage protects the host from plasmids and dsDNA viruses,
whereas RNA cleavage defends from ssRNA viruses. In this
view, transcript cleavage could be an unintended consequence
of the type III-A system’s versatile nucleic acid targeting
capability. Of note, cas10palm mutant cells, which are capable
of RNA-guided RNA cleavage activity only, display a low level
of immunity against phage infection (Figure 6, compare with
Dspc1 control cells). It is tempting to speculate that CRISPR-
mediated phage mRNA degradation could contribute to anti-
phage immunity in certain conditions. An immune function for
mRNA targeting, if any, remains to be determined.
The first observation of crRNA-guided RNA cleavage was ob-
tained with experiments with the Pyrococcus furiosus type III-B
CRISPR-Cas system (Hale et al., 2009) and was subsequently
corroborated for other homolog systems (Zhang et al., 2012).
Type III-B CRISPR-Cas loci encode for a Cas10-Cmr complex,
homolog to the Cas10-Csm complex of type III-A systems. Ge-
netic experiments with Sulfolobus islandicus, an archaeon that
contains two type III-B CRISPR-Cas loci suggest that transcrip-
tion is required for anti-plasmid immunity (Deng et al., 2013) and
that these systems can cleave RNA transcripts derived from
anti-tag targets (Peng et al., 2015). Combining these observa-
tions for type III-B CRISPR immunity, the conservation between
both CRISPR subtypes and our data, we propose a unified mo-
lecular mechanism for all type III CRISPR-Cas systems: co-tran-
scriptional crRNA-guided DNA and RNA targeting performed
by Cas10-Csm/Cmr complexes. This is in sharp opposition to
the type I and II CRISPR-Cas systems that have been studied
so far, which rely strictly on DNA sequence recognition (Edgar
andQimron, 2010; Garneau et al., 2010; Jinek et al., 2012; Seme-
nova et al., 2011). The broad-target recognition capabilities
of type III CRISPR-Cas systems provide a versatile immune
response against many different viruses, plasmids, and other
mobile genetic elements that coexist with bacteria and archaea.
EXPERIMENTAL PROCEDURES
Purification of Recombinant Cas10-Csm Complex from E. coli
Plasmid pPS22 (Hatoum-Aslan et al., 2013) was used to express the Cas10-
Csm complex in E. coli. To generate the csm3D32A mutation (in plasmid
pPS086) pPS22 was used as template for PCR with two set of primers
PS153/PS465 and PS154/PS466 (the sequences of all oligonucleotides
used in this study are in Table S1), and the products were joined by Gibson as-
sembly (Gibson et al., 2009). Full sequencing of the cloned DNA fragments was
performed to corroborate the presence of the mutation. The cas10D586A-D587A
mutation (in plasmid pPS096) was generated in a similar way using the sets of
primers PS556/PS559 and PS557/PS558.The wild-type and mutant Cas10-
Csm protein complexes were purified as previously described (Hatoum-Aslan
et al., 2013) with minor modifications (see Supplemental Experimental
Procedures).
Oligonucleotide Substrates
DNA and RNA oligonucleotides were purchased from IDT. They were
radiolabeled at the 50 end with T4 polynucleotide kinase (NEB) and g-32P ATP1172 Cell 161, 1164–1174, May 21, 2015 ª2015 Elsevier Inc.(PerkinElmer) in a 1 3 T4 polynucleotide kinase buffer at 37C for 1 hr in a
50-ml reaction. The ssDNAand ssRNAsubstrateswere subjected to denaturing
gel purification. The oligonucleotide bandswere visualized by autoradiography
and excised, eluted into 1M ammonium acetate (pH 8), 0.2%SDS, and 20mM
EDTA at 4C overnight, ethanol precipitated, and resuspended in 10 mM Tris-
HCl (pH 8) (for DNA) (pH 6.8) (for RNA), 1 mM EDTA. To generate dsDNA sub-
strates T4 PNK was first heat inactivated (at 65C for 20 min), and then the
reactions were purified using an IllustraMicrospin G50 column (GEHealthcare)
to remove excessg-32PATP. Duplex substrateswere generated by heating an-
nealing labeled oligonucleotideswith twice-molar excess of unlabeledcomple-
mentary oligonucleotides in the annealing buffer (20 mM Tris-Cl [pH 7.5],
100 mM KCl, 5 mM MgCl2, and 5% glycerol) at 90
C for 10 min, followed by
slow cooling to room temperature. Duplexes were separated from single-
stranded DNA by 6% native PAGE conducted at 4C. The duplex bands
were visualized by autoradiography and excised, eluted into 10 mM Tris-HCl
(pH 8), 1 mM EDTA at 4C overnight, ethanol precipitated, and resuspended
in 10 mM Tris-HCl (pH 8), 1 mM EDTA. The sequences of DNA and RNA oligo-
nucleotides used in this study are listed in Tables S1 and S2, respectively.
Transcription Coupled DNA Cleavage
Elongation complexes (ECs) were reconstituted essentially as described in Si-
dorenkov et al. (1998). Typically, 2 ml 1 pmol/ml of template strand (TS) and 1 ml
of 4 pmol/ml RNA oligos were mixed in 1 3 transcription buffer and incubated
at 65C for 5min, followed by gradual cooling to room temperature. After addi-
tion of 1.5 ml E. coli RNAP core enzyme (NEB), the reaction was incubated at
25C for 25–30 min and at 37C for 1 min. Then, 4 ml 1.25 pmol/ml nontemplate
strand (NTS) (pretreated by heating to 65C for 5min, then on ice for 2min, and
finally at 37C for 2 min) was added and incubated for 10–15 min at 37C. The
final concentration of TS was 0.10 pmol/ml after adding supplement buffer to
obtain transcription conditions. Assembled ECs were kept on ice until use.
In a transcription coupled DNA cleavage assay, Cas10-Csm complex was
added to a final concentration of 15 ng/ml. Transcription was initiated with
the addition of 2.5 mM of RNTPs. All the reactions were performed at 37C.
For the elongation complex with labeled RNA primer, Cas10-Csm and RNTPs
were added to the elongation complex in two different orders. In lanes indi-
cated by (a), the Cas10-Csm complex was added to the elongation complex
(EC) and incubated for 10min; prior to the addition of RNTPs. In lanes indicated
by (b), RNTPs were added to the elongation complex and the reaction was
incubated for 10 min, followed by the addition of the Cas10-Csm complex.
For all the DNA cleavage time course experiments, RNTPs were added to
the elongation complex (EC), prior to the addition of Cas10-Csm complex. Af-
ter addition of Cas10-Csm, the samples were collected at timed intervals of
30 min, 1 hr, 1 hr 30 min, and 2 hr and quenched by mixing with Proteinase
K (NEB) and 20 mM EDTA. The DNA/RNA samples were then extracted using
phenol-chloroform-isoamyl alcohol (25:24:1), ethanol precipitated and resus-
pended into loading buffer (90% formamide). The DNA products were heater
at 95C for 5min before loading onto the gel. Cleavage products were resolved
on a 12% denaturing polyacrylamide gels containing 7 M urea and visualized
by phosphorimaging (Typhoon, GE Life Sciences).
RNA Cleavage
RNA cleavage reactions were performed at 37C with 0.1 pmol of 50-radiola-
beled RNA and 100 ng of Cas10-Csm complex in the reaction buffer (25 mM
Tris-HCl [pH 7.5], 10 mM MgCl2, 2 mM TCEP). Reactions were initiated by
addition of the Cas10/Csm complex. The samples were collected at timed in-
tervals and quenched by mixing 10 ml of reaction mixture with 2 3 loading
buffer (90% formamide, 50 mM EDTA). The reaction products were separated
on a 14% denaturing PAGE and visualized by phosphorimaging (Typhoon, GE
Life Sciences). 32P-50-labeled RNA Decade marker (Ambion) was used as a
size marker. To map the cleavage products, oligoribonucleotide markers
were generated by RNase A (Life Technologies), RNase T1 (Life Technologies)
treatment of RNA substrates for 10 min at 22C, or by alkaline hydrolysis in
50 mM NaHCO3 (pH 9.5) at 95
C for 10 min.
Transformation
Cultivation of S. aureus RN4220 (Kreiswirth et al., 1983), was carried out
in tryptic soy (TS) broth at 37C. Whenever applicable, media were
supplemented with chloramphenicol at 10 mg/ml or erythromycin at 5 mg/ml to
ensure pC194- (Horinouchi and Weisblum, 1982a) (pCRISPR) and pE194-
derived (Horinouchi and Weisblum, 1982b) (pTarget) plasmid maintenance,
respectively. Transformations were performed as previously described (Gold-
berg et al., 2014) using 100 ml of competent cells and 500 mg of plasmid DNA.
After electroporation transformants were plated on TS agar plates containing
chloramphenicol and erythromycin for the selection of pCRISPR and pTarget
derivatives, respectively, with or without anhydrotetracycline (aTc). Plates
without aTc were incubated at 37C for 12 hr and plates with aTc at 37C
for 36 hr before counting colony-forming units. Construction of plasmid
pCRISPR and its cas10palm derivative was described previously (Hatoum-
Aslan et al., 2013). The csm3D32Amutationwas introduced into pCRISPR using
pPS22 as template for two PCRs with two set of primers PS153/PS465 and
PS154/PS466; the products were joined by Gibson assembly to generate
pPS87. pTarget construction was reported previously (Goldberg et al., 2014)
as pWJ153. Its pTargetanti-tag derivative was generated by Gibson assembly
of a PCR product obtained using pWJ153 as template and primers NP36
and NP37.
Inducible CRISPR Immunity
The experiment was performed as previously described (Goldberg et al.,
2014), with the following modifications. Overnight cultures were started from
a single transformant colony obtained in the absence of aTc, grown in 3 ml
of TS broth supplemented with chloramphenicol and erythromycin. Cultures
are diluted to an OD600 0.1 OD in 5ml TSB with only chloramphenicol and
grown for 1 hr. At this point (time zero in the assay) CRISPR targeting is
induced by adding aTc to a final concentration of 0.25 mg/ml. Cells were
collected at different times after induction and either plasmid DNA or total
RNA was purified using a minprep kit (QIAGEN) or TRIzol (Life Technologies),
respectively. Primer extension assays were performed as reported elsewhere
(Hatoum-Aslan et al., 2011) using primers A248 and A67 for the detection of
target cleavage and 5S rRNA, respectively.
Phage Infections
Infection of S. aureus RN4220 cells with bacteriophage FNM1g6 was per-
formed as described previously (Goldberg et al., 2014). The spacer targeting
the gp43 gene of the phage was introduced by phosphorylating and annealing
the oligonucleotides oGG250 and oGG251 and ligating them into the pGG-
BsaI-R vector digested with BsaI, generating pWJ191 (wild-type type III-A
pCRISPR plasmid in Figure 6B). pGG-BsaI-R was used as the no-spacer con-
trol (Dspc1). This vector was derived from pGG3-BsaI (Goldberg et al., 2014)
via two consecutive steps of ‘round-the-horn PCR (Moore et al., 2008) fol-
lowed by blunt ligation. First, spacer 1 was removed from pGG3-BsaI to create
pGG-BsaI, using primers oGG164 and oGG165. Second, a downstream
repeat was added using primers W845 and W846 to create pGG-BsaI-R.
The cas10palm derivative was constructed by Gibson assembly of two PCR
products: one using primers W494 and W1020 and pLM547 (Hatoum-Aslan
et al., 2013) as template, and another using primers W1021 and W1022 and
pWJ191 as template. The csm3D32A mutation was introduced into pCRISPR
using pWJ191 as template for two PCRs with two set of primers PS153/
PS465 and PS154/PS466; the products were joined by Gibson assembly to
generate pPS87. Construction of the plasmid harboring the type II-A
CRISPR-Cas system of S. pyogenes targeting the gp43 gene (pGG37) was
described elsewhere (Goldberg et al., 2014).
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